| Li, Jin |
NCT04914598: A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions |
|
|
| Not yet recruiting | 3 | 290 | RoW | ENDOSTAR，cisplatin, Placebo , cisplatin | Jiangsu Simcere Pharmaceutical Co., Ltd. | Malignant Pleural Effusion | 06/22 | 10/23 | | |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
SHR-A1811-309, NCT06199973: Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan |
|
|
| Recruiting | 3 | 120 | RoW | SHR-A1811, TAS-102, Regorafenib , Fruquintinib | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Colorectal Cancer | 04/26 | 06/26 | | |
LM302-03-101, NCT06351020: LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. |
|
|
| Recruiting | 3 | 375 | RoW | LM-302, Apatinib, Irinotecan | LaNova Medicines Zhejiang Co., Ltd. | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | 08/26 | 12/26 | | |
NCT05919381: Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma. |
|
|
| Recruiting | 3 | 752 | RoW | Gentuximab Injection, Gentuximab Injection Placebo | GeneScience Pharmaceuticals Co., Ltd. | Adenocarcinoma of Stomach | 12/24 | 01/25 | | |
SHR-A1811-308, NCT06123494: SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen |
|
|
| Recruiting | 3 | 360 | RoW | SHR-A1811, Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan | Jiangsu HengRui Medicine Co., Ltd. | HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | 06/27 | 06/27 | | |
NCT05554913: Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia |
|
|
| Completed | 2/3 | 63 | RoW | QL0911, Placebo | Qilu Pharmaceutical Co., Ltd. | Chemotherapy-induced Thrombocytopenia | 02/24 | 02/24 | | |
HLX22-GC-201, NCT04908813: Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer |
|
|
| Active, not recruiting | 2 | 150 | RoW | HLX22, Placebo, Trastuzumab, Oxaliplatin, Capecitabine | Shanghai Henlius Biotech | Gastric Cancer | 12/24 | 12/25 | | |
NCT04329429: A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 57 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Biliary Tract Cancer | 11/23 | 06/24 | | |
NCT05068206: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx |
|
|
| Recruiting | 2 | 120 | RoW | AK105 injection, Anlotinib hydrochloride capsule, CapeOX, Bevacizumab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unresectable Metastatic Colorectal Cancer | 12/23 | 06/24 | | |
MRG002-007, NCT05141747: A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. |
|
|
| Recruiting | 2 | 60 | RoW | MRG002 | Shanghai Miracogen Inc. | Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer | 12/23 | 12/23 | | |
NCT04911907: Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 120 | RoW | utidelone injection | Beijing Biostar Pharmaceuticals Co., Ltd., Chengdu Biostar Pharmaceuticals | Solid Tumor | 03/24 | 12/24 | | |
NCT05799820: QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC |
|
|
| Recruiting | 2 | 60 | RoW | QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine | Qilu Pharmaceutical Co., Ltd. | Colorectal Carcinoma | 03/24 | 09/25 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
| Not yet recruiting | 2 | 60 | NA | Neratinib tablets, Neratinib | Convalife (Shanghai) Co., Ltd. | Advanced Solid Tumor | 02/26 | 04/26 | | |
FOENIX-CCA4, NCT05727176: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement |
|
|
| Recruiting | 2 | 120 | Europe, Japan, US, RoW | TAS-120, Futibatinib | Taiho Oncology, Inc. | Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement | 12/26 | 12/26 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
NCT06132932: A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations |
|
|
| Completed | 1/2 | 38 | RoW | WX390, WXFL10030390 | Shanghai Jiatan Pharmatech Co., Ltd | PIK3CA Mutation-Related Tumors | 01/23 | 01/23 | | |
HLX07Ib/II, NCT03577704: The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. |
|
|
| Completed | 1/2 | 56 | RoW | HLX07+Gemcitabine+Cisplatin, Recombinant anti-EGFR humanized monoclonal antibody, Gemzar, Cisplatin, HLX07+Paclitaxel+Carboplatin, Paclitaxel, Carboplatin, HLX07+mFOLFOX6, Oxaliplatin for Injection, Folinic acid calcium salt hydrate, 5-fluouracil | Shanghai Henlius Biotech | Advanced Solid Tumors | 09/22 | 12/22 | | |
NCT04882176: A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours |
|
|
| Terminated | 1/2 | 18 | RoW | LM-061, Kinase inhibitor | LaNova Medicines Limited | Advanced Tumours | 02/23 | 07/23 | | |
BGB-900-104, NCT03941873: A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer |
|
|
| Completed | 1/2 | 111 | RoW | Sitravatinib, MGCD516, Tislelizumab, BGB-A317, Tevimbra | BeiGene | Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer | 03/23 | 03/23 | | |
|
NCT04198818: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors |
|
|
| Terminated | 1/2 | 37 | US, RoW | HH2710 | Haihe Biopharma Co., Ltd. | Advanced Tumors, Melanoma, Non-Small-Cell Lung Cancer, Erdheim-Chester Disease, Other RAS/RAF/MEK/ERK Mutated Tumors | 03/23 | 03/23 | | |
FRUSICA-1, NCT03903705: : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 381 | RoW | Fruquintinib in Combination with Sintilimab, Fruquintinib | Hutchmed | Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT05396391: A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 140 | RoW | IAP0971 | SUNHO（China）BioPharmaceutical CO., Ltd. | Advanced Malignant Tumors | 05/24 | 11/24 | | |
NCT05396339: A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. |
|
|
| Recruiting | 1/2 | 120 | RoW | IAE0972 | SUNHO（China）BioPharmaceutical CO., Ltd. | Advanced Malignant Solid Tumor | 05/24 | 11/24 | | |
NCT05338957: A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. |
|
|
| Recruiting | 1/2 | 30 | RoW | MRG002+HX008 | Shanghai Miracogen Inc. | Advanced Malignant Solid Tumors | 06/24 | 12/24 | | |
NCT05991583: A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 25 | RoW | IBB0979 | SUNHO（China）BioPharmaceutical CO., Ltd. | Advanced Malignant Tumors | 11/25 | 12/25 | | |
NCT05107011: Phase I/II Clinical Trial of LBL-015 for Injection |
|
|
| Completed | 1/2 | 25 | RoW | LBL-015 for Injections, LBL-015 | Nanjing Leads Biolabs Co.,Ltd, Shanghai East Hospital, Shandong Cancer Hospital and Institute, Henan Cancer Hospital, Hunan Cancer Hospital, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital Bengbu Medical College | Advanced Malignant Tumor | 12/23 | 12/23 | | |
NCT06650566: Study of LM-299 in Subjects Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 230 | RoW | LM-299 | LaNova Medicines Limited | Malignant Tumors | 12/26 | 07/27 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Recruiting | 1/2 | 56 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumor | 12/24 | 12/24 | | |
| Active, not recruiting | 1/2 | 206 | RoW | LM-302 Injection | LaNova Medicines Zhejiang Co., Ltd. | Advanced Solid Tumor | 03/25 | 06/25 | | |
NCT05955105: A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies |
|
|
| Recruiting | 1/2 | 200 | RoW | ILB-2109, Toripalimab | Innolake Biopharm | Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Melanoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Classic Hodgkin Lymphoma | 01/26 | 07/26 | | |
NCT03869632: First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | YL-13027 | Shanghai YingLi Pharmaceutical Co. Ltd. | Advanced Solid Tumors | 04/21 | 06/22 | | |
NCT04758897: Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161 | CNBG-Virogin Biotech (Shanghai) Ltd. | Advanced Malignant Solid Tumor | 03/22 | 12/22 | | |
NCT05051241: A Study of GFH018 in Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 50 | RoW | GFH018 | Zhejiang Genfleet Therapeutics Co., Ltd. | Advanced Solid Tumor | 08/22 | 08/22 | | |
NCT03852823: Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours |
|
|
| Recruiting | 1 | 192 | RoW | SG001, Recombinant Human Anti-PD-1 Monoclonal Antibody | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma, Lymphoma, Non-Small-Cell Lung Cancer | 09/22 | 03/23 | | |
| Recruiting | 1 | 74 | RoW | MRG002 | Shanghai Miracogen Inc. | Advanced Solid Tumor | 10/22 | 10/22 | | |
NCT04630522: Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors |
|
|
| Completed | 1 | 295 | RoW | Drug: JMT103- 120 mg SC Q4W, Drug: JMT103- 120 mg SC Q8W, Drug: JMT103- 180 mg SC Q8W, Dietary Supplement: Calcium Dietary Supplement: Vitamin D | Shanghai JMT-Bio Inc. | Bone Metastases From Solid Tumors | 03/23 | 03/23 | | |
NCT05137275: Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 56 | RoW | Anti-5T4 CAR-raNK Cells | Shanghai East Hospital, Imbioray (Hangzhou) Biomedicine Co., Ltd. | Locally Advanced or Metastatic Solid Tumors | 04/23 | 05/23 | | |
NCT03792958: Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors |
|
|
| Active, not recruiting | 1 | 19 | RoW | CM082, X-82 | AnewPharma, Shanghai East Hospital | Advanced Malignant Solid Tumors | 06/23 | 06/23 | | |
| Active, not recruiting | 1 | 101 | RoW | SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer, Colorectal Cancer | 06/24 | 12/24 | | |
NCT04802980: A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor |
|
|
| Recruiting | 1 | 72 | RoW | HB002.1T, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin | Huabo Biopharm Co., Ltd. | Solid Tumor | 07/23 | 09/23 | | |
NCT04467853: A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors |
|
|
| Terminated | 1 | 34 | RoW | LCAR-C18S cells | Shanghai East Hospital, Nanjing Legend Biotech Co. | Solid Tumors, Adult | 07/23 | 07/23 | | |
NCT04400383: Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors |
|
|
| Completed | 1 | 62 | RoW | AB011 Injection, recombinant humanized anti-Claudin 18.2 monoclonal antibody injection, recombinant humanized anti-CLDN 18.2 monoclonal antibody injection | CARsgen Therapeutics Co., Ltd., Shanghai East Hospital | Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma | 07/23 | 09/23 | | |
NCT06209385: A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 157 | RoW | YZJ-5053 tablets, SHY-1901 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Solid Tumor | 10/27 | 01/28 | | |
NCT05278546: A Study of ILB2109 in Patients With Advanced Solid Malignancies |
|
|
| Active, not recruiting | 1 | 48 | RoW | ILB2109 | Innolake Biopharm, Shanghai East Hospital, Shandong Cancer Hospital and Institute | Advanced Solid Tumor | 12/24 | 02/25 | | |
NCT05142592: Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 196 | US, RoW | IPG7236 | Nanjing Immunophage Biotech Co., Ltd | Safety Issues, Tolerability, Pharmacokinetics | 09/25 | 12/25 | | |
NCT04221204: A Monotherapy in Subjects With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 42 | US, RoW | Highly selective FGFR1-3 inhibitor | 3D Medicines (Beijing) Co., Ltd. | Solid Tumor, Adult | 12/24 | 12/24 | | |
NCT05116709: Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors |
|
|
| Completed | 1 | 28 | RoW | BAT6005 injection | Bio-Thera Solutions | Locally Advanced or Metastatic Solid Tumors | 01/24 | 09/24 | | |
NCT05554666: A Study of ASKG315 in Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1 | 56 | RoW | ASKG315 | AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/23 | 10/24 | | |
NCT03607188: Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer |
|
|
| Completed | 1 | 17 | RoW | Alkotinib, ZG0418 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Non-small Cell Lung Cancer | 10/22 | 10/22 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
NCT06621615: Clinical Study of CVL006 Injection in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 120 | NA | CVL006 Injection, B006 | Convalife (Shanghai) Co., Ltd. | Advanced Solid Tumor | 05/28 | 11/28 | | |
NCT05108779: QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 40 | RoW | QLF32004 | Qilu Pharmaceutical Co., Ltd. | Advanced Tumor | 12/24 | 12/24 | | |
NCT05621486: A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 36 | RoW | B4T2-001 Autologous CAR T cells | Shanghai East Hospital, Bio4T2 LLC | Advanced Solid Tumor | 12/24 | 12/26 | | |
NCT04947033: A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 25 | RoW | TJ210001 Injection | I-Mab Biopharma Co. Ltd. | Advanced Solid Tumor | 12/24 | 12/25 | | |
NCT05764915: A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors |
|
|
| Terminated | 1 | 11 | RoW | RGT-264 phosphate tablets | Regor Pharmaceuticals Inc. | Advanced Solid Tumor | 02/24 | 02/24 | | |
NCT06072989: Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors |
|
|
| Recruiting | 1 | 24 | RoW | B4T2-001 autologous CAR-T | Shanghai East Hospital, Bio4T2 LLC | Advanced Solid Tumor | 03/25 | 03/27 | | |
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors |
|
|
| Terminated | 1 | 20 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Advanced Solid Tumor, BRAF V600 Mutation | 06/24 | 06/24 | | |
NCT06235242: GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 20 | RoW | GT201 injection in combination with teraplizumab injection | Grit Biotechnology | Adult, Non-small Cell Lung Cancer | 01/27 | 01/27 | | |
| Liu, Xiaomeng |
| No trials found |
